<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526418</url>
  </required_header>
  <id_info>
    <org_study_id>U002</org_study_id>
    <nct_id>NCT04526418</nct_id>
  </id_info>
  <brief_title>Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Temporal Lobe Epilepsy</brief_title>
  <official_title>Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Temporal Lobe Epilepsy An Open-label, Prospective, Paired, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNEEG Medical A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNEEG Medical A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the&#xD;
      Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12&#xD;
      weeks of outpatient EEG recording.&#xD;
&#xD;
      The present study is a 12-week open-label, prospective study with a paired, comparative&#xD;
      design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system&#xD;
      in subjects with temporal lobe epilepsy.&#xD;
&#xD;
      2 years (from study start up to closure) 5-6 sites in the United States/Europe.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open-label, prospective study with a paired comparative design for pivotal evaluation of the satety and effectiveness of the 24/7 EEC SubQ system in subjects with temporal lobe epilepsy.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of seizures</measure>
    <time_frame>comparasion in EMU for 3-14 days period, where patients are hospitalized.</time_frame>
    <description>numbers of seizures as detected in EEG data from SubQ to be compared with number of seizures detected in golden standard (video EEG).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>2 years</time_frame>
    <description>safety reporting</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>24/7 EEG™ SubQ System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To demonstrate the electrographic seizure recording effectiveness of the 24/7 EEG™ SubQ system by comparison to simultaneous inpatient video-EEG data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>24/7 EEG™ SubQ system</intervention_name>
    <description>Electrographic seizure recording sensitivity of an ipsilaterally implanted 24/7 EEG™ SubQ system: proportion of identified ipsilateral seizures as compared to ipsilateral video-EEG during admission to the Epilepsy Monitoring Unit</description>
    <arm_group_label>24/7 EEG™ SubQ System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is 18-75 years old.&#xD;
&#xD;
          -  Semiology of seizures compatible with temporal lobe involvement&#xD;
&#xD;
          -  Paraclinical findings supporting temporal seizure focus. Such proof may consist of: -&#xD;
             previous EEG recording interpreted as compatible with temporal involvement OR -&#xD;
             radiological findings demonstrating pathology in the temporal area (CT, MRI, FDG-PET&#xD;
             or SPECT).&#xD;
&#xD;
          -  Uncontrolled epileptic seizures.&#xD;
&#xD;
          -  Subject has planned clinical EMU admission with an admission goal including capturing&#xD;
             epileptic seizures, within 12 weeks after the date of UNEEG™ SubQ implant.&#xD;
&#xD;
          -  Subject is willing and able to provide written informed consent.&#xD;
&#xD;
          -  Subject is able to complete all study-required procedures, assessments and follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a condition that places him/her at a high at high risk of surgical&#xD;
             complications, such as an active systemic infection or a hemorrhagic disease.&#xD;
&#xD;
          -  Subject receives frequent (more than 2 days per week) treatment with drugs of the&#xD;
             following types:&#xD;
&#xD;
               1. antiplatelets&#xD;
&#xD;
               2. anticoagulants&#xD;
&#xD;
               3. chemotherapeutics&#xD;
&#xD;
               4. non-steroid anti-inflammatory drugs (NSAID)&#xD;
&#xD;
          -  Subject has skeletal deformities or damage at the proposed implantation site to an&#xD;
             extent that impedes correct electrode placement.&#xD;
&#xD;
          -  Subject has an active deep brain stimulation device.&#xD;
&#xD;
          -  Subject has or is exposed to a medical device that delivers electrical energy into the&#xD;
             area around the implant.&#xD;
&#xD;
          -  Subject has a cochlear implant(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Pathmanathan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lykke Blaabjerg</last_name>
    <phone>+45 41414244</phone>
    <email>lybl@uneeg.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Worrell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvenia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JAY PATHMANATHAN</last_name>
      <phone>215-662-3606</phone>
      <email>Jay.Pathmanathan@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universität Klinikum Freibrug</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Schulze-Bonhage</last_name>
      <phone>+49 761 270 53660</phone>
      <email>andreas.schulze-bonhage@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Temporal Lobe</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

